Kinase Inhibitors in Cancer Therapy: A Look Ahead

Sedlacek, H.
March 2000
Drugs;Mar2000, Vol. 59 Issue 3, p435
Academic Journal
The most essential kinases involved in cell membrane receptor activation, signal transduction and cell cycle control or programmed cell death and their interconections are reviewed. In tumours, the genes of many of those kinases are mutated or amplified or the proteins are overexpressed. The use of key kinases offers the possibility to screen in vitro for synthetic small molecule kinase inhibitors. In view of the many interconnections of cellular kinases, their role in preventing or inducing programmed cell death and the possibility that a considerable number of signal transducing proteins are still unknown, cellular test systems are recommended in which the respective key kinase or one of its main partner molecules are overexpressed.


Related Articles

  • Bisindolylmaleimides in anti-cancer therapy - more than PKC inhibitors. Pajak, B.; Orzechowska, S.; Gajkowska, B.; Orzechowski, A. // Advances in Medical Sciences (De Gruyter Open);2008, Vol. 53 Issue 1, p21 

    Bisindolylmaleimide derivatives were originally described as protein kinase C inhibitors. However, several studies have shown that bisindolylmaleimides target several other signaling molecules. The review presents bisindolylmaleimide-mediated PKC-dependent and PKC-independent biological effects,...

  • Ruxolitinib for the treatment of primary myelofibrosis. SWAIM, STARLA J. // American Journal of Health-System Pharmacy;3/15/2014, Vol. 71 Issue 6, p453 

    Purpose. The pharmacology, pharmacokinetics, pharmacogenomics, clinical efficacy, and safety profile of ruxolitinib for the treatment of primary myelofibrosis are reviewed. Summary. Ruxolitinib, an oral tyrosine kinase inhibitor that targets the Janus-associated kinases (JAKs) 1 and 2, has been...

  • Mitogen-activated protein kinases in apoptosis regulation. Wada, Teiji; Penninger, Josef M. // Oncogene;4/12/2004 Review, Vol. 23 Issue 16, p2838 

    Cells are continuously exposed to a variety of environmental stresses and have to decide ‘to be or not to be’ depending on the types and strength of stress. Among the many signaling pathways that respond to stress, mitogen-activated protein kinase (MAPK) family members are crucial...

  • Inhibition of AMPK signalling by doxorubicin: at the crossroads of the cardiac responses to energetic, oxidative, and genotoxic stress. Gratia, Séverine; Kay, Laurence; Potenza, Lucia; Seffouh, Amal; Novel-Chaté, Valérie; Schnebelen, Coralie; Sestili, Piero; Schlattner, Uwe; Tokarska-Schlattner, Malgorzata // Cardiovascular Research;8/1/2012, Vol. 95 Issue 3, p290 

    Aims Cardiotoxic side effects of anthracyclines, the most widely used anticancer drugs, are well documented, while mechanisms involved are not fully elucidated. The cellular energy sensor and regulator AMP-activated protein kinase (AMPK) was suggested as a putative mediator of cardiotoxicity of...

  • Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model. Kususda, Y; Miyake, H; Gleave, M E; Fujisawa, M // British Journal of Cancer;6/5/2012, Vol. 106 Issue 12, p1945 

    Background:The objective of this study was to investigate whether the therapeutic activity of sorafenib could be enhanced by combining with OGX-011, an antisense oligodeoxynucleotide (ODN) targeting clusterin, in renal cell carcinoma (RCC).Methods:We investigated the effects of combined...

  • Yhhu3813 is a novel selective inhibitor of c-Met Kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells. He, Chang-xi; Ai, Jing; Xing, Wei-qiang; Chen, Yi; Zhang, Hao-tian; Huang, Min; Hu, You-hong; Ding, Jian; Geng, Mei-yu // Acta Pharmacologica Sinica;Jan2014, Vol. 35 Issue 1, p89 

    Aim:c-Met kinase deregulation is strongly associated with the formation, progression and dissemination of human cancers. In this study we identified Yhhu3813 as a small-molecule inhibitor of c-Met kinase and characterized its antitumor properties both in vitro and in vivo.Methods:The activities...

  • STAT3 Inhibitors: Finding a Home in Lymphoma and Leukemia. Munoz, Javier; Dhillon, Navjot; Janku, Filip; Watowich, Stephanie S.; Hong, David S. // Oncologist;2014, Vol. 19 Issue 5, p536 

    The Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway is an active mediator of cytokine signaling in the pathogenesis of solid and hematologic malignancies. The seven-member STAT family is composed of latent cytoplasmic transcription factors that are...

  • Assessing adaptation of the cancer kinome in response to targeted therapies. Zawistowski, Jon S.; Graves, Lee M.; Johnson, Gary L. // Biochemical Society Transactions;Aug2014, Vol. 42 Issue 4, p765 

    Cancer cells are dependent on protein kinase signalling networks to drive proliferation and to promote survival, and, accordingly, kinases continue to represent a major target class for development of anticancer therapeutics. Kinase inhibitors nevertheless have yielded only limited success with...

  • Novel Library of Selenocompounds as Kinase Modulators. Plano, Daniel; Ibáñez, Elena; Calvo, Alfonso; Palop, Juan Antonio; Sanmartín, Carmen // Molecules;Aug2011, Vol. 16 Issue 8, p6349 

    Although the causes of cancer lie in mutations or epigenic changes at the genetic level, their molecular manifestation is the dysfunction of biochemical pathways at the protein level. The 518 protein kinases encoded by the human genome play a central role in various diseases, a fact that has...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics